Claims
- 1. A cyclopentapyran ester C.sub.22 H.sub.30 O.sub.8 of the formula ##STR3## said ester, in the substantially pure state, having a refraction index n.sub.D.sup.20 =1.4923 and an optical rotation of [.alpha.].sub.D.sup.21 =+151.degree. (in methanol), said ester, on degradation by heating to 100.degree. C. and chromatographical separation, yielding 4-isovaleroxy methyl-7-formyl cyclopenta(c)pyran as thermal degradation product.
- 2. In a process of producing the cyclopentapyran ester of the formula ##STR4## said process comprising the steps of extracting comminuted roots or rhizoma of plants of the genus Valeriana with a lipophilic solvent having added thereto an aliphatic carboxylic acid having 2 to 7 carbon atoms in its molecule at a slightly acidic pH range, concentrating the resulting extract, dissolving the concentrated extract in concentrated acetic acid, treating the resulting acid solution with a lipophilic solvent, discarding the lipophilic solvent solution, diluting the acetic acid phase with water, and extracting the cyclopentapyran esters from said diluted aqueous acid solution with a water-insoluble organic solvent, the improvement which consists in subjecting the roots or rhizomas of the Valeriana plants of the species Valeriana mexicana or Valeriana toluccana D.C. to said extraction and purification process.
- 3. The process of claim 2, in which the resulting extract in the water-insoluble organic solvent is subjected to chromatographic adsorption on an aluminum oxide adsorbent, said aluminum oxide adsorbent being partly inactivated by a treatment with an aliphatic carboxylic acid having 2 to 7 carbon atoms in a water-free medium, wherefrom the cyclopentapyran ester of the formula given in Claim 2 is fractionally eluted.
- 4. The process of claim 3, in which the eluting agent is a lipophilic solvent.
- 5. The process of claim 4, in which the lipophilic solvent is hexane.
- 6. In a method of producing a balanced tranquilizing and sedative effect without causing drowsiness in humans or animals, the step which comprises administering to humans or animals an effective amount of the compound of claim 1.
- 7. In a method of treating humans or animals affected by bacterial infections and especially by infections caused by bacteria of the Mycobacterium group, the step which comprises administering to such humans or animals an effective amount of the compound of claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
1768092 |
Mar 1968 |
DEX |
|
Parent Case Info
The present application is a continuation-in-part of application Ser. No. 519,986 entitled "NEW THERAPEUTICALLY ACTIVE COMPOUNDS" and filed Jan. 11, 1966; and a continuation of application Ser. No. 601,548, filed Apr. 8, 1975 and entitled "NEW CYCLOPENTAPYRANS", which application in turn is a continuation of application Ser. No. 401,904, filed Sept. 28, 1973 and of application Ser. No. 764,199, filed Oct. 1, 1968, which in turn is a continuation-in-part of application Ser. No. 519,986, entitled "NEW THERAPEUTICALLY ACTIVE COMPOUNDS" and filed Jan. 11, 1966, said applications Ser. No. 601,548, Ser. No. 401,904, Ser. No. 764,199, and Ser. No. 519,986 being abandoned.
US Referenced Citations (4)
Non-Patent Literature Citations (2)
Entry |
Thies, Tetrahedron, vol. 24, pp. 313 to 347 (Jan. 1968). |
Thies, Tetrahedron Letters, No. 11, pp. 1163-1170 (1966). |
Related Publications (1)
|
Number |
Date |
Country |
|
764199 |
Oct 1968 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
401904 |
Sep 1973 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
519986 |
Jan 1966 |
|
Parent |
519986 |
|
|